Ertapenem Therapy for Community-Acquired Pneumonia in the Elderly

Journal of the American Geriatrics Society

Volumn 51, Issue 11, 2003, Pages 1526-1532

  Woods, Gail L ^b   Isaacs, Robin D ^b   McCarroll, Kathleen A ^b   Friedland, Ian R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

Clinical trial; Community acquired pneumonia; Elderly; Ertapenem

Indexed keywords

AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; ERTAPENEM; PENICILLIN DERIVATIVE;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CEFTRIAXONE; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACTAMS; LOGISTIC MODELS; MALE; ODDS RATIO; PNEUMONIA, PNEUMOCOCCAL; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 0242408504     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1532-5415.2003.51507.x     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention. Pneumonia and influenza death rates-United States, 1979-94. MMWR Morb Mortal Wkly Rep 1995;44:535-537.
2. Marston BJ, Plouffe JF, File TM et al. Incidence of community-acquired pneumonia requiring hospitalization: Results of a population-based active surveillance study in Ohio. Arch Intern Med 1997;157:1709-1718.
3. Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System. National Vital Statistics Reports. Hyattsville, MD: US Department of Health and Human Services, Center for Disease Control and Prevention, National Center for Health Statistics, 1998.
4. Kaplan V, Angus DC, Griffin MF et al. Hospitalized community-acquired pneumonia in the elderly. Age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med 2002;165:766-772.
5. Livermore DM, Carter MW, Bagel S et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 2001;45:1860-1867.
6. Fuchs PC, Barry AL, Brown SD. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001;45:1915-1918.
7. Ortiz-Ruiz G, Caballero-Lopez J, Friedland I et al. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis 2002;34:1076-1083.
8. Vetter N, Cambronero-Hernandez E, Rohlf J et al. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for treatment of hospitalized adults with community-acquired pneumonia. Clin Therapeutics 2002;24:1770-1785.
9. Friedland I, Isaacs R, Singer A et al. Double-blind, multicenter, randomized studies of ertapenem versus ceftriaxone for the treatment of serious community-acquired pneumonia [abstract]. Clin Infect Dis 2001;33:1166.
10. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-250.
11. National Committee for Clinical Laboratory Standards. Performance Standard for Antimicrobial Disk Susceptibility Tests. Approved Standard (NCCLS document M2-A6). Wayne, PA: National Committee for Clinical Laboratory Standards, 1997.
12. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 5th Ed. (NCCLS document M7-A5). Wayne, PA: National Committee for Clinical Laboratory Standards, 2000.
13. De Palma M, Rocchi D, Canepa G et al. Single daily dose of cefodizime in patients with community-acquired pneumonia: An open-label, controlled, randomized study. Clin Ther 1995;17:413-424.
14. Segev S, Raz R, Rubinstein E et al. Double-blind randomized study of 1 g versus 2 g intravenous ceftriaxone daily in the therapy of community-acquired infections. Eur J Clin Microbiol Infect Dis 1994;14:851-855.
15. Zuck P, Rio Y, Ichou F. Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia. J Antimicrob Chemother 1990;26(Suppl. E):71-77.
16. Zervos M, Nelson M, and the Cefepime Study Group. Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia. Antimicrob Agents Chemother 1998;42:729-733.
17. Bassetti D, Cruciani M, Solbiati F et al. Comparative efficacy of ceftriaxone versus ceftazidime in the treatment of nosocomial lower respiratory tract infections. Chemotherapy (Basel) 1991;37:371-375.
18. Mangi RJ, Peccerillo KM, Ryan J et al. Cefoperazone versus ceftriaxone monotherapy of nosocomial pneumonia. Diagn Microbiol Infect Dis 1992;15:441-447.
19. Phillips SL, Branaman-Phillips J. The use of intramuscular cefoperazone versus intramuscular ceftriaxone in patients with nursing home-acquired pneumonia. J Am Geriatr Soc 1993;41:1071-1074.
20. Valenti WM, Trudell RG, Bentley DW. Factors predisposing to oropharyngeal colonization with gram negative bacilli in the aged. N Engl J Med 1978;298:1108-1111.
21. Torres A, El-Ebiary M, Riqueime R et al. Community-acquired pneumonia in the elderly. Semin Respir Infect 1999;14:173-183.
22. Feldman C. Pneumonia in the elderly. Med Clin North Am 2001;85:1441-1459.
23. Marrie TJ. Community-acquired pneumonia in the elderly. Clin Infect Dis 2000;31:1066-1078.
24. Kikuchi R, Warabe N, Konno T et al. High incidence of silent aspiration in elderly patients with community-acquired pneumonia. Am J Respir Crit Care Med 1994;150:251-253.
25. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995;333:1618-1624.
26. Ries K, Levison ME, Kaye D. Transtracheal aspiration in pulmonary infection. Arch Intern Med 1974;133:453-458.
27. Lieberman D, Lieberman D. Community-acquired pneumonia in the elderly. A practical guide to treatment. Drugs Aging 2000;17:93-105.
28. Marston BJ, Plouffe JE, File TM et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. Arch Intern Med 1997;157:1709-1718.
29. Friedland I, Majumdar A, Motyl M et al. Ertapenem is highly active against common clinical bacterial pathogens. Clin Microbiol Infect 2002;8(Suppl. 1):40.